CTRI/2007/091/000039招募中2 期
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in PreviouslyUntreated Subjects With Lung Cancer
The pharmaceutical company sponsoring this study is Bristol-MyersSquibb0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Documented NSCLC or SCLC
- •ECOG of 0 or 1
排除标准
- •�� Brain metastases
- •�� Autoimmune disease
- •�� Known HIV, Hep B or Hep C infection
- •�� Peripheral neuropathy ≥ grade 2
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol/Paraplatin (Paclitaxel/Carboplatin) Compared to Taxol/Paraplatin Alone in Previously Untreated Subjects with Lung Cancer - NDEUCTR2007-001256-39-ITBristol-Myers Squibb International Corporation413
进行中（未招募）
不适用
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)EUCTR2007-001256-39-DEBristol-Myers Squibb International Corporation413
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carboplatin) Compared to Taxol®/Paraplatin® Alone in Previously Untreated Subjects with Lung Cancer+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 2.0 dated 20-Jul-07EUCTR2007-001256-39-FRBristol-Myers Squibb International Corporation413
已完成
不适用
Bioequivalence study with clinical endpoint of generic diclofenac gel withVoltaren® gel in patients with osteoarthritis of knee.CTRI/2017/04/008304Mylan Laboratories Pvt Ltd1,220
进行中（未招募）
Unknown
A clinical study to check the safety and effectiveness of test treatments in adult human subjects having anemia or iron-deficiency anemiaCTRI/2023/10/059283ORGENETICS INC